262 related articles for article (PubMed ID: 30890554)
1. Contrasting requirements during disease evolution identify EZH2 as a therapeutic target in AML.
Basheer F; Giotopoulos G; Meduri E; Yun H; Mazan M; Sasca D; Gallipoli P; Marando L; Gozdecka M; Asby R; Sheppard O; Dudek M; Bullinger L; Döhner H; Dillon R; Freeman S; Ottmann O; Burnett A; Russell N; Papaemmanuil E; Hills R; Campbell P; Vassiliou GS; Huntly BJP
J Exp Med; 2019 Apr; 216(4):966-981. PubMed ID: 30890554
[TBL] [Abstract][Full Text] [Related]
2. Expression of Enhancer of Zeste Homolog 2 (EZH2) Gene in Acute Myeloid Leukemia.
Hamed NAM; El Ghandour A; Abo Elwafa RA; Rezk MR; Ghallab O
Asian Pac J Cancer Prev; 2023 Jan; 24(1):81-85. PubMed ID: 36708555
[TBL] [Abstract][Full Text] [Related]
3. Loss of the histone methyltransferase EZH2 induces resistance to multiple drugs in acute myeloid leukemia.
Göllner S; Oellerich T; Agrawal-Singh S; Schenk T; Klein HU; Rohde C; Pabst C; Sauer T; Lerdrup M; Tavor S; Stölzel F; Herold S; Ehninger G; Köhler G; Pan KT; Urlaub H; Serve H; Dugas M; Spiekermann K; Vick B; Jeremias I; Berdel WE; Hansen K; Zelent A; Wickenhauser C; Müller LP; Thiede C; Müller-Tidow C
Nat Med; 2017 Jan; 23(1):69-78. PubMed ID: 27941792
[TBL] [Abstract][Full Text] [Related]
4. Integrative study of EZH2 mutational status, copy number, protein expression and H3K27 trimethylation in AML/MDS patients.
Stomper J; Meier R; Ma T; Pfeifer D; Ihorst G; Blagitko-Dorfs N; Greve G; Zimmer D; Platzbecker U; Hagemeijer A; Schmitt-Graeff I; Lübbert M
Clin Epigenetics; 2021 Apr; 13(1):77. PubMed ID: 33845873
[TBL] [Abstract][Full Text] [Related]
5. Quantitative proteomic analysis of EZH2 inhibition in acute myeloid leukemia reveals the targets and pathways that precede the induction of cell death.
Sandow JJ; Infusini G; Holik AZ; Brumatti G; Averink TV; Ekert PG; Webb AI
Proteomics Clin Appl; 2017 Sep; 11(9-10):. PubMed ID: 28447382
[TBL] [Abstract][Full Text] [Related]
6. E2F4 functions as a tumour suppressor in acute myeloid leukaemia via inhibition of the MAPK signalling pathway by binding to EZH2.
Feng Y; Li L; Du Y; Peng X; Chen F
J Cell Mol Med; 2020 Feb; 24(3):2157-2168. PubMed ID: 31943751
[TBL] [Abstract][Full Text] [Related]
7. A non-viral nano-delivery system targeting epigenetic methyltransferase EZH2 for precise acute myeloid leukemia therapy.
Kaundal B; Kushwaha AC; Srivastava AK; Karmakar S; Choudhury SR
J Mater Chem B; 2020 Sep; 8(37):8658-8670. PubMed ID: 32844866
[TBL] [Abstract][Full Text] [Related]
8. Nanoformulation of EPZ011989 Attenuates EZH2-c-Myb Epigenetic Interaction by Proteasomal Degradation in Acute Myeloid Leukemia.
Kaundal B; Srivastava AK; Dev A; Mohanbhai SJ; Karmakar S; Roy Choudhury S
Mol Pharm; 2020 Feb; 17(2):604-621. PubMed ID: 31904978
[TBL] [Abstract][Full Text] [Related]
9. Loss-of-function mutations in the histone methyltransferase EZH2 promote chemotherapy resistance in AML.
Kempf JM; Weser S; Bartoschek MD; Metzeler KH; Vick B; Herold T; Völse K; Mattes R; Scholz M; Wange LE; Festini M; Ugur E; Roas M; Weigert O; Bultmann S; Leonhardt H; Schotta G; Hiddemann W; Jeremias I; Spiekermann K
Sci Rep; 2021 Mar; 11(1):5838. PubMed ID: 33712646
[TBL] [Abstract][Full Text] [Related]
10. EZH2, new diagnosis and prognosis marker in acute myeloid leukemia patients.
Mechaal A; Menif S; Abbes S; Safra I
Adv Med Sci; 2019 Sep; 64(2):395-401. PubMed ID: 31331874
[TBL] [Abstract][Full Text] [Related]
11. Novel combination of histone methylation modulators with therapeutic synergy against acute myeloid leukemia in vitro and in vivo.
Wen S; Wang J; Liu P; Li Y; Lu W; Hu Y; Liu J; He Z; Huang P
Cancer Lett; 2018 Jan; 413():35-45. PubMed ID: 29069576
[TBL] [Abstract][Full Text] [Related]
12. Analysis of TET2 and EZH2 gene functions in chromosome instability in acute myeloid leukemia.
Wang J; He N; Wang R; Tian T; Han F; Zhong C; Zhang C; Hua M; Ji C; Ma D
Sci Rep; 2020 Feb; 10(1):2706. PubMed ID: 32066746
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of EZH2 by chidamide exerts antileukemia activity and increases chemosensitivity through Smo/Gli-1 pathway in acute myeloid leukemia.
Jiang X; Jiang L; Cheng J; Chen F; Ni J; Yin C; Wang Q; Wang Z; Fang D; Yi Z; Yu G; Zhong Q; Carter BZ; Meng F
J Transl Med; 2021 Mar; 19(1):117. PubMed ID: 33743723
[TBL] [Abstract][Full Text] [Related]
14. HO-1 promotes resistance to an EZH2 inhibitor through the pRB-E2F pathway: correlation with the progression of myelodysplastic syndrome into acute myeloid leukemia.
He Z; Zhang S; Ma D; Fang Q; Yang L; Shen S; Chen Y; Ren L; Wang J
J Transl Med; 2019 Nov; 17(1):366. PubMed ID: 31711520
[TBL] [Abstract][Full Text] [Related]
15. Ezh2 loss promotes development of myelodysplastic syndrome but attenuates its predisposition to leukaemic transformation.
Sashida G; Harada H; Matsui H; Oshima M; Yui M; Harada Y; Tanaka S; Mochizuki-Kashio M; Wang C; Saraya A; Muto T; Hayashi Y; Suzuki K; Nakajima H; Inaba T; Koseki H; Huang G; Kitamura T; Iwama A
Nat Commun; 2014 Jun; 5():4177. PubMed ID: 24953053
[TBL] [Abstract][Full Text] [Related]
16. EZH2 dysregulation: Potential biomarkers predicting prognosis and guiding treatment choice in acute myeloid leukaemia.
Chu MQ; Zhang TJ; Xu ZJ; Gu Y; Ma JC; Zhang W; Wen XM; Lin J; Qian J; Zhou JD
J Cell Mol Med; 2020 Jan; 24(2):1640-1649. PubMed ID: 31794134
[TBL] [Abstract][Full Text] [Related]
17. Clinical Significance of EZH2 in Acute Myeloid Leukemia.
Jiao W; Liu Y; Bao Y
Comput Intell Neurosci; 2022; 2022():8741989. PubMed ID: 36052036
[TBL] [Abstract][Full Text] [Related]
18. Ezh2 augments leukemogenicity by reinforcing differentiation blockage in acute myeloid leukemia.
Tanaka S; Miyagi S; Sashida G; Chiba T; Yuan J; Mochizuki-Kashio M; Suzuki Y; Sugano S; Nakaseko C; Yokote K; Koseki H; Iwama A
Blood; 2012 Aug; 120(5):1107-17. PubMed ID: 22677129
[TBL] [Abstract][Full Text] [Related]
19. Tetraspanin Family Member, CD82, Regulates Expression of EZH2 via Inactivation of p38 MAPK Signaling in Leukemia Cells.
Nishioka C; Ikezoe T; Yang J; Yokoyama A
PLoS One; 2015; 10(5):e0125017. PubMed ID: 25955299
[TBL] [Abstract][Full Text] [Related]
20. Alternative splicing redefines landscape of commonly mutated genes in acute myeloid leukemia.
Rivera OD; Mallory MJ; Quesnel-Vallières M; Chatrikhi R; Schultz DC; Carroll M; Barash Y; Cherry S; Lynch KW
Proc Natl Acad Sci U S A; 2021 Apr; 118(15):. PubMed ID: 33876749
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]